{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:06:43Z","timestamp":1793434003002,"version":"4.5.0"},"reference-count":39,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,3,19]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adoptive cell therapy with T cells genetically engineered to express a chimeric antigen receptor (CAR-T) or tumor-infiltrating T lymphocytes (TIL) demonstrates impressive clinical results in patients with cancer. Lymphodepleting preconditioning prior to cell infusion is an integral part of all adoptive T cell therapies. However, to date, there is no standardization and no data comparing different non-myeloablative (NMA) regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we compared NMA therapies with different doses of cyclophosphamide or total body irradiation (TBI) in combination with fludarabine and evaluated bone marrow suppression and recovery, cytokine serum levels, clinical response and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We demonstrate that a cumulative dose of 120\u2009mg\/kg cyclophosphamide and 125\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      fludarabine (120Cy\/125Flu) and 60Cy\/125Flu preconditioning were equally efficient in achieving deep lymphopenia and neutropenia in patients with metastatic melanoma, whereas absolute lymphocyte counts (ALCs) and absolute neutrophil counts were significantly higher following 200 cGyTBI\/75Flu-induced NMA. Thrombocytopenia was most profound in 120Cy\/125Flu patients. 30Cy\/75Flu-induced preconditioning in patients with acute lymphoblastic leukemia resulted in a minor ALC decrease, had no impact on platelet counts and did not yield deep neutropenia. Following cell infusion, 120Cy\/125Flu patients with objective tumor response had significantly higher ALC and significant lower inflammatory indexes, such as neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Receiver-operating characteristics curve analysis 7\u2009days after cell infusion was performed to determine the cut-offs, which distinguish between responding and non-responding patients in the 120Cy\/125Flu cohort. NLR\u22641.79\u2009and PLR\u226432.7 were associated with clinical response and overall survival. Cytokine serum levels did not associate with clinical response in patients with TIL. Patients in the 120Cy\/125Flu cohort developed significantly more acute NMA-related adverse events, including thrombocytopenia, febrile neutropenia and cardiotoxicity, and stayed significantly longer in hospital compared with the 60Cy\/125Flu and TBI\/75Flu cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bone marrow depletion and recovery were equally affected by 120Cy\/125Flu and 60Cy\/125Flu preconditioning; however, toxicity and consequently duration of hospitalization were significantly lower in the 60Cy\/125Flu cohort. Patients in the 30Cy\/75Flu and TBI\/75Flu groups rarely developed NMA-induced adverse events; however, both regimens were not efficient in achieving deep bone marrow suppression. Among the regimens, 60Cy\/125Flu preconditioning seems to achieve maximum effect with minimum toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2020-001743","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T11:10:27Z","timestamp":1620990627000},"page":"e001743","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":63,"title":["Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00287131","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03166397","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03166397","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02772198","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00287131","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03166397","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02772198","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Abraham","family":"Nissani","sequence":"first","affiliation":[{"name":"Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaked","family":"Lev-Ari","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Meirson","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"},{"name":"Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Jacoby","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, The Edmond and Lily Safra Children\u2019s Hospital, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"},{"name":"Department of Hematology, Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4094-8045","authenticated-orcid":false,"given":"Nethanel","family":"Asher","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Ben-Betzalel","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Itzhaki","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Shapira-Frommer","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"},{"name":"Oncology Division, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Schachter","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Markel","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"},{"name":"Deparment of Clinical Microbiology and Immunology, Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-0458","authenticated-orcid":false,"given":"Michal J.","family":"Besser","sequence":"additional","affiliation":[{"name":"Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Tel Hashomer, Israel"},{"name":"Deparment of Clinical Microbiology and Immunology, Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"2025100309472164000_9.5.e001743.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067"},{"key":"2025100309472164000_9.5.e001743.2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/mc.23193","article-title":"Comprehensive single Institute experience with melanoma TIL: long term clinical results, toxicity profile, and prognostic factors of response","volume":"59","author":"Besser","year":"2020","journal-title":"Mol Carcinog"},{"key":"2025100309472164000_9.5.e001743.3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11864-012-0203-7","article-title":"Adoptive immunotherapy of advanced melanoma","volume":"13","author":"Shapira-Frommer","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"2025100309472164000_9.5.e001743.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.03.002"},{"key":"2025100309472164000_9.5.e001743.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076514"},{"key":"2025100309472164000_9.5.e001743.6","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502905","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100309472164000_9.5.e001743.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.9093"},{"key":"2025100309472164000_9.5.e001743.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2722"},{"key":"2025100309472164000_9.5.e001743.9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000148"},{"key":"2025100309472164000_9.5.e001743.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.5449"},{"key":"2025100309472164000_9.5.e001743.11","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181b88ffc"},{"key":"2025100309472164000_9.5.e001743.12","doi-asserted-by":"publisher","DOI":"10.1038\/nri1842"},{"key":"2025100309472164000_9.5.e001743.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0792-6"},{"key":"2025100309472164000_9.5.e001743.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.12.003"},{"key":"2025100309472164000_9.5.e001743.15","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.molonc.2015.10.018","article-title":"Tumor-Infiltrating lymphocytes for the treatment of metastatic cancer","volume":"9","author":"Geukes Foppen","year":"2015","journal-title":"Mol Oncol"},{"key":"2025100309472164000_9.5.e001743.16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.5.2591"},{"key":"2025100309472164000_9.5.e001743.17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050732"},{"key":"2025100309472164000_9.5.e001743.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024"},{"key":"2025100309472164000_9.5.e001743.19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600219"},{"key":"2025100309472164000_9.5.e001743.20","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.3748\/wjg.v23.i34.6261","article-title":"Systemic immune-inflammation index for predicting prognosis of colorectal cancer","volume":"23","author":"Chen","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2025100309472164000_9.5.e001743.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1742-x","article-title":"Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection","volume":"16","author":"Diao","year":"2018","journal-title":"J Transl Med"},{"key":"2025100309472164000_9.5.e001743.22","doi-asserted-by":"crossref","first-page":"75381","DOI":"10.18632\/oncotarget.18856","article-title":"Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis","volume":"8","author":"Zhong","year":"2017","journal-title":"Oncotarget"},{"key":"2025100309472164000_9.5.e001743.23","doi-asserted-by":"crossref","DOI":"10.1186\/s40880-017-0243-2","article-title":"Prognostic value of systemic immune-inflammation index in patients with gastric cancer","volume":"36","author":"Wang","year":"2017","journal-title":"Chin J Cancer"},{"key":"2025100309472164000_9.5.e001743.24","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1245\/s10434-018-6660-x","article-title":"Baseline neutrophil-lymphocyte and platelet-lymphocyte ratios as biomarkers of survival in cutaneous melanoma: a multicenter cohort study","volume":"25","author":"Wade","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2025100309472164000_9.5.e001743.25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/CMR.0000000000000333","article-title":"Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma","volume":"27","author":"Lino-Silva","year":"2017","journal-title":"Melanoma Res"},{"key":"2025100309472164000_9.5.e001743.26","first-page":"1","article-title":"Prognostic significance of pretreatment neutrophil\/lymphocyte ratio and Platelet\/Lymphocyte ratio in patients with diffuse large B-cell lymphoma","volume":"2018","author":"Wang","year":"2018","journal-title":"Biomed Res Int"},{"key":"2025100309472164000_9.5.e001743.27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21849"},{"key":"2025100309472164000_9.5.e001743.28","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1002\/cam4.878","article-title":"The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma","volume":"5","author":"Khoja","year":"2016","journal-title":"Cancer Med"},{"key":"2025100309472164000_9.5.e001743.29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1684\/ejd.2017.3167","article-title":"A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma","volume":"28","author":"Finon","year":"2018","journal-title":"Eur J Dermatol"},{"key":"2025100309472164000_9.5.e001743.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0380"},{"key":"2025100309472164000_9.5.e001743.31","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ajh.25274","article-title":"Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia","volume":"93","author":"Jacoby","year":"2018","journal-title":"Am J Hematol"},{"key":"2025100309472164000_9.5.e001743.32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci"},{"key":"2025100309472164000_9.5.e001743.33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-883710"},{"key":"2025100309472164000_9.5.e001743.34","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-019-04187-z"},{"key":"2025100309472164000_9.5.e001743.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0442"},{"key":"2025100309472164000_9.5.e001743.36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200936","article-title":"Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer","volume":"13","author":"Cho","year":"2018","journal-title":"PLoS One"},{"key":"2025100309472164000_9.5.e001743.37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00995","article-title":"Prognostic value of peripheral inflammatory markers in preoperative mucosal melanoma: a multicenter retrospective study","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol"},{"key":"2025100309472164000_9.5.e001743.38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00262-019-02478-7","article-title":"The neutrophil-lymphocyte ratio and locoregional melanoma: a multicentre cohort study","volume":"69","author":"Robinson","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2025100309472164000_9.5.e001743.39","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0383-1"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:47:28Z","timestamp":1759510048000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,14]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/jitc-2020-001743"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001743","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}